HANDOK (A002390) Stock Overview
Operates as a pharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
A002390 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
HANDOK Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩11,050.00 |
| 52 Week High | ₩14,250.00 |
| 52 Week Low | ₩10,500.00 |
| Beta | 0.39 |
| 1 Month Change | -1.95% |
| 3 Month Change | -3.24% |
| 1 Year Change | -5.88% |
| 3 Year Change | -35.68% |
| 5 Year Change | -62.29% |
| Change since IPO | 917.84% |
Recent News & Updates
Recent updates
Is HANDOK (KRX:002390) A Risky Investment?
Oct 16
Is HANDOK (KRX:002390) Using Too Much Debt?
Jul 01HANDOK Inc.'s (KRX:002390) 27% Share Price Surge Not Quite Adding Up
May 28Is HANDOK Inc.'s (KRX:002390) 1.0% Dividend Worth Your Time?
Apr 01How Much Of HANDOK Inc. (KRX:002390) Do Insiders Own?
Mar 15HANDOK (KRX:002390) Has A Somewhat Strained Balance Sheet
Feb 28Did You Miss HANDOK's (KRX:002390) 21% Share Price Gain?
Feb 13HANDOK Inc. (KRX:002390) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Jan 31We're Not So Sure You Should Rely on HANDOK's (KRX:002390) Statutory Earnings
Jan 18Here's Why I Think HANDOK (KRX:002390) Might Deserve Your Attention Today
Jan 05
Should HANDOK Inc. (KRX:002390) Be Part Of Your Dividend Portfolio?
Dec 23What Kind Of Investors Own Most Of HANDOK Inc. (KRX:002390)?
Dec 10HANDOK (KRX:002390) Has A Somewhat Strained Balance Sheet
Nov 27Shareholder Returns
| A002390 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -2.6% | -2.0% | -1.6% |
| 1Y | -5.9% | 35.7% | 96.7% |
Return vs Industry: A002390 underperformed the KR Pharmaceuticals industry which returned 35.7% over the past year.
Return vs Market: A002390 underperformed the KR Market which returned 96.7% over the past year.
Price Volatility
| A002390 volatility | |
|---|---|
| A002390 Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A002390 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A002390's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 950 | Young-Jin Kim | www.handok.co.kr |
HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food supplements under the NatureSet brand; food and beverages; and medical nutrition products.
HANDOK Inc. Fundamentals Summary
| A002390 fundamental statistics | |
|---|---|
| Market cap | ₩143.55b |
| Earnings (TTM) | -₩43.54b |
| Revenue (TTM) | ₩516.37b |
Is A002390 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A002390 income statement (TTM) | |
|---|---|
| Revenue | ₩516.37b |
| Cost of Revenue | ₩364.72b |
| Gross Profit | ₩151.65b |
| Other Expenses | ₩195.19b |
| Earnings | -₩43.54b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.35k |
| Gross Margin | 29.37% |
| Net Profit Margin | -8.43% |
| Debt/Equity Ratio | 141.1% |
How did A002390 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/06 22:25 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HANDOK Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Byung Hwa Han | Eugene Investment & Securities Co Ltd. |
| Seung-Ho Lee | NH Investment & Securities Co., Ltd. |
| Eun Saem Lee | Shinhan Investment Corp. |